Drug Profile
LF 060337
Latest Information Update: 16 Aug 2023
Price :
$50
*
At a glance
- Originator Fournier Pharma
- Developer GlaxoSmithKline
- Class Antithrombotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Deep vein thrombosis; Thrombosis
Most Recent Events
- 19 Nov 2003 No development reported for Thrombosis in USA (PO)
- 15 Nov 2001 Investigation in Thrombosis in USA (PO)
- 21 Dec 1999 Discontinued-I for Deep vein thrombosis in France (PO)